Business Wire

Transition Industries Awards Techint E&C and Siemens Energy a FEED Contract for a 210 MW Electrolyzer Facility for the Pacifico Mexinol Project

28.8.2025 15:00:00 CEST | Business Wire | Press Release

Share

Transition Industries LLC, a developer of world-scale, net-zero carbon emissions methanol and hydrogen facilities, has awarded Siemens Energy and Techint Engineering & Construction a Front-End Engineering Design (FEED) contract for an approximately 210 MW Elyzer P-300 electrolyzer facility as part of its 6,130 MT per day ultra-low carbon methanol Pacifico Mexinol project in Sinaloa, Mexico.

The FEED study marks the next step in the expanding partnership between Transition Industries, Techint Engineering & Construction, and Siemens Energy, who intend to leverage their advanced technology and services to ensure the highest standards of efficiency and reliability in green hydrogen production. Under the terms of the FEED Agreement, Siemens Energy and Techint Engineering & Construction will provide an initial binding not-to-exceed Lump Sum Firm Price, followed by a final binding Lump Sum Turnkey Firm Price for the Engineering, Procurement and Construction (EPC) of the electrolyzer facility.

Once operational in 2029, Pacifico Mexinol is poised to be the largest standalone ultra-low carbon chemical production facility and one of the largest producers of green hydrogen and green methanol in the world.

Rommel Gallo, Transition Industries CEO, said: “This milestone marks a significant step forward in our mission to drive innovation and sustainability in the chemicals sector. Partnering with Siemens Energy and Techint E&C positions us to develop the hydrogen production element of our Pacifico Mexinol project, thereby reducing emissions and contributing to the global energy transition.”

The Hydrogen Plant will be designed to produce green hydrogen to support the growing demand for sustainable hydrogen. The FEED study will focus on optimizing the design, standardization, and engineering aspects of the Hydrogen Plant with an estimated production capacity of approximately 4,000 kg of hydrogen/hour with the highest safety, environmental and operational standards.

Siemens Energy, one of the world’s leading energy technology companies, was selected for this aspect of the project, capitalizing on their expertise in green hydrogen production. Siemens Energy’s Elyzer P-300 technology will play a crucial role in achieving the project’s goals of efficiency, sustainability, and scalability.

"At Techint E&C, we talk about a passion for doing, but even more so when it comes to challenging and high-impact projects like Mexinol, which are the ones that allow us to contribute with all our technical expertise, be part of a key energy transition project as the largest green hydrogen plant in America, and continue building a better future for everyone," highlighted Alejandro Maluf, President – North America Region, Techint E&C.

Transition Industries is jointly developing Pacifico Mexinol with the International Finance Corporation (IFC), a member of the World Bank Group. When it initiates operations in 2029, Pacifico Mexinol is expected to be the largest single ultra-low carbon methanol facility in the world – producing approximately 350,000 MT of green methanol and 1.8 million MT of blue methanol annually from natural gas with carbon capture.

ABOUT TRANSITION INDUSTRIES

Transition Industries LLC, based in Houston, Texas, is a developer of world-scale, net-zero carbon emissions methanol and green hydrogen projects in North America to address climate change and promote environmental and social sustainability. For additional information about Pacifico Mexinol or Transition Industries, email inquiries@transitionind.com.

ABOUT TECHINT

Techint Engineering & Construction is a global leader in project management, engineering, procurement, and construction across sectors such as Oil & Gas, Energy, Mining, and Industrial Plants. With over 75 years of experience and a team of more than 20,000 professionals worldwide, Techint is committed to executing highly complex projects with the highest standards of safety, quality, and environmental responsibility.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250828068284/en/

Contacts

Transition Industries Press Relations
Karin Nunan
Head of Corporate Affairs
knunan@transitionind.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye